Privium Fund Management B.V. Increases Position in Urogen Pharma (NASDAQ:URGN)

Key Points

• Privium Fund Management B.V. significantly increased its stake in Urogen Pharma by 288.7%, owning 107,622 shares valued at approximately $1.19 million.
• Multiple hedge funds, including CWM LLC and GAMMA Investing LLC, also dramatically boosted their holdings, reflecting growing institutional interest in Urogen Pharma, which now has 91.29% institutional ownership.
• Equities research analysts have a positive outlook on Urogen Pharma, with a consensus rating of "Buy" and target prices ranging from $16.00 to $31.00 per share.

Privium Fund Management B.V. increased its stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 288.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 107,622 shares of the company's stock after purchasing an additional 79,931 shares during the period. Privium Fund Management B.V. owned approximately 0.23% of Urogen Pharma worth $1,190,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in URGN. CWM LLC boosted its position in shares of Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after buying an additional 5,140 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Urogen Pharma in the fourth quarter valued at approximately $59,000. Lazard Asset Management LLC bought a new stake in Urogen Pharma in the fourth quarter valued at approximately $67,000. GAMMA Investing LLC raised its stake in Urogen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in Urogen Pharma in the fourth quarter valued at approximately $101,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on URGN shares. Guggenheim reaffirmed a "buy" rating and issued a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Urogen Pharma in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Urogen Pharma in a research report on Tuesday, July 8th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Urogen Pharma currently has an average rating of "Buy" and an average price target of $32.86.

Urogen Pharma Trading Up 4.2%

NASDAQ:URGN traded up $0.84 during trading hours on Tuesday, hitting $20.72. 1,787,165 shares of the company were exchanged, compared to its average volume of 1,594,410. The stock has a market capitalization of $957.26 million, a price-to-earnings ratio of -6.52 and a beta of 1.12. Urogen Pharma has a one year low of $3.42 and a one year high of $21.02. The company has a fifty day simple moving average of $12.83 and a 200 day simple moving average of $11.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The firm had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Equities research analysts predict that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the transaction, the general counsel directly owned 41,492 shares in the company, valued at $794,156.88. The trade was a 15.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 5,162 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the transaction, the insider owned 153,378 shares of the company's stock, valued at $1,130,395.86. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,833 shares of company stock valued at $280,567 over the last quarter. 4.70% of the stock is owned by company insiders.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.